TMEDvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with TMED, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
TMED performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/08/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | TMED ETF 2 | -1.44%– | +11.05%– | +17.46%– | +35.43%– | n/a– | n/a– |
| Flows | TMED ETF 2 | +$4M– | +$10M– | +$13M– | +$15M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | TMED ETF 2 | +18.14%– | +18.39%– | n/a– | n/a– |
| Max drawdown | TMED ETF 2 | -4.97%– | -11.09%– | n/a– | n/a– |
| Max drawdown duration | TMED ETF 2 | 20d– | 125d– | n/a– | n/a– |
Trading data
TMED | ETF 2 | |
Last sale 9/10/2026 at 1:30 PM | $34.00 | – |
| Previous close 09/09/2026 | $34.39 | – |
| Consolidated volume 09/09/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Advertisement
Main metrics
Last update 9/10/2026 at 1:30 PM
Live
Closed
TMED | ETF 2 | |
|---|---|---|
| Last price | $34.00 | – |
| 1D performance | -1.13% | – |
| AuM | $33.12 M | – |
| E/R | 0.44% | – |
Characteristics
TMED | ETF 2 | |
|---|---|---|
| Management strategy | Active | – |
| Provider | T. Rowe Price | – |
| Benchmark | - | – |
| N° of holdings | 97 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 11, 2025 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
TMED
USA
93.59%
Other
6.41%
ETF 2
Sectors
TMED
Healthcare
98.58%
Other
1.42%
ETF 2
Advertisement
Diversification
TMED
Total weight of top 15 holdings out of 15
61.11%
ETF 2
–
Top 15 holdings
Data as of July 31, 2026
TMED
Eli Lilly & Co.
16.65%
UnitedHealth Group, Inc.
5.89%
Thermo Fisher Scientific, Inc.
4.44%
Alnylam Pharmaceuticals, Inc.
4.11%
Gilead Sciences, Inc.
3.76%
Danaher Corp.
3.58%
Cencora, Inc.
3.30%
Insulet Corp.
2.73%
Agilent Technologies, Inc.
2.69%
DexCom, Inc.
2.66%
Dyne Therapeutics, Inc.
2.60%
Stryker Corp.
2.49%
West Pharmaceutical Services, Inc.
2.29%
Waters Corp.
2.20%
McKesson Corp.
1.72%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
